DaVita Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

DaVita wird ein jährliches Gewinn- und Umsatzwachstum von 2.4% bzw. 4.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 59.5% betragen.

Wichtige Informationen

2.4%

Wachstumsrate der Gewinne

10.0%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	4.1%
Zukünftige Eigenkapitalrendite	59.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16

Recent updates

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

Mar 13

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Mar 04

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16

Is DaVita (NYSE:DVA) Using Too Much Debt?

Feb 08

DaVita: Assessing After The Rally

Dec 29

DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity

Dec 24

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

Nov 08

DaVita: Simple And Compelling After Sell-Off

Oct 26

Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)

Oct 25

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Oct 05

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Aug 14

DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt

Jul 31

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Jul 21

Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down

Jul 18

DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate

Jul 03

What Is DaVita Inc.'s (NYSE:DVA) Share Price Doing?

May 01

These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Extensively

Apr 17

Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)

Apr 03

Are Investors Undervaluing DaVita Inc. (NYSE:DVA) By 40%?

Mar 08

DaVita HealthCare Partners Q4 2022 Earnings Preview

Feb 21

Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine

Feb 08

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Jan 24

Is DaVita (NYSE:DVA) A Risky Investment?

Jan 09

DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution

Dec 12

DaVita Q3 2022 Earnings Preview

Oct 27

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Oct 18

DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling

Sep 28

DaVita could benefit from legislation that would return dialysis protection to Medicare

Aug 16

We Think DaVita (NYSE:DVA) Is Taking Some Risk With Its Debt

Aug 14

DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation

Jul 28

DaVita: Valuation Turning Attractive

Jul 16

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Jul 13

Here's Why I Think DaVita (NYSE:DVA) Is An Interesting Stock

May 15

DaVita Offers Stability During Market Volatility

May 12

Gewinn- und Umsatzwachstumsprognosen

NYSE:DVA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	13,691	825	N/A	2,275	4
12/31/2025	13,214	811	N/A	1,966	7
12/31/2024	12,682	775	N/A	1,946	7
3/31/2024	12,338	816	920	1,462	N/A
12/31/2023	12,140	692	1,491	2,059	N/A
9/30/2023	11,911	596	1,314	1,918	N/A
6/30/2023	11,739	454	1,357	1,967	N/A
3/31/2023	11,665	500	1,077	1,705	N/A
12/31/2022	11,610	547	961	1,565	N/A
9/30/2022	11,637	680	1,152	1,751	N/A
6/30/2022	11,627	834	995	1,607	N/A
3/31/2022	11,616	903	1,479	2,099	N/A
12/31/2021	11,619	978	1,289	1,931	N/A
9/30/2021	11,580	984	1,209	1,886	N/A
6/30/2021	11,566	883	1,124	1,802	N/A
3/31/2021	11,529	791	1,108	1,773	N/A
12/31/2020	11,551	783	1,304	1,979	N/A
9/30/2020	11,544	832	1,506	2,175	N/A
6/30/2020	11,524	824	1,648	2,333	N/A
3/31/2020	11,487	816	2,112	2,834	N/A
12/31/2019	11,388	705	1,730	2,496	N/A
9/30/2019	11,311	623	1,406	2,235	N/A
6/30/2019	11,253	548	1,124	2,011	N/A
3/31/2019	11,300	551	255	1,208	N/A
12/31/2018	11,412	616	544	1,531	N/A
9/30/2018	11,378	617	621	1,592	N/A
6/30/2018	11,299	698	698	1,679	N/A
3/31/2018	11,110	652	547	1,470	N/A
12/31/2017	10,884	909	N/A	1,966	N/A
9/30/2017	7,773	1,065	N/A	1,983	N/A
6/30/2017	8,732	1,480	N/A	2,016	N/A
3/31/2017	9,747	1,382	N/A	2,391	N/A
12/31/2016	10,696	1,038	N/A	1,988	N/A
9/30/2016	14,550	716	N/A	1,918	N/A
6/30/2016	14,347	361	N/A	2,061	N/A
3/31/2016	14,065	478	N/A	1,576	N/A
12/31/2015	9,973	323	N/A	1,531	N/A
9/30/2015	13,565	484	N/A	1,051	N/A
6/30/2015	13,290	452	N/A	1,219	N/A
3/31/2015	13,027	429	N/A	1,450	N/A
12/31/2014	12,781	723	N/A	1,459	N/A
9/30/2014	12,519	727	N/A	1,884	N/A
6/30/2014	12,270	680	N/A	1,769	N/A
3/31/2014	11,971	787	N/A	1,813	N/A
12/31/2013	11,759	620	N/A	1,773	N/A
9/30/2013	11,174	564	N/A	1,619	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DVADas prognostizierte Gewinnwachstum (2.4% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: DVADie Erträge des Unternehmens (2.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: DVADie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: DVADie Einnahmen des Unternehmens (4.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: DVADie Einnahmen des Unternehmens (4.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DVADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (59.5%).

DaVita Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 9.0% to US$140

Price target increased by 7.4% to US$131

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 14% to US$120

Consensus EPS estimates increase by 13%

Price target increased by 7.3% to US$113

Recent updates

Now 21% overvalued after recent price rise

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Now 22% overvalued after recent price rise

Are DaVita Inc. (NYSE:DVA) Investors Paying Above The Intrinsic Value?

Now 21% overvalued after recent price rise

Returns On Capital At DaVita (NYSE:DVA) Have Hit The Brakes

Independent Director recently sold US$698k worth of stock

DaVita Appoints Madhu Narasimhan as Chief Information Officer, Effective June 3, 2024

Independent Director notifies of intention to sell stock

Price target increased by 9.0% to US$140

High number of new directors

DaVita Inc., Annual General Meeting, Jun 06, 2024

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

DaVita Stock Is A Hold As It Expands In Latin America

Chief Operating Officer of Kidney Care exercised options and sold US$3.0m worth of stock

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

CEO & Executive Director exercised options and sold US$36m worth of stock

Price target increased by 7.4% to US$131

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Chief Compliance Officer recently sold US$3.0m worth of stock

Chief Compliance Officer notifies of intention to sell stock

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 14% to US$120

Is DaVita (NYSE:DVA) Using Too Much Debt?

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

DaVita: Assessing After The Rally

DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity

CEO & Executive Director exercised options and sold US$16m worth of stock

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

DaVita: Simple And Compelling After Sell-Off

Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 19%

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Chief Legal & Public Affairs Officer notifies of intention to sell stock

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Price target increased by 7.3% to US$113

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt

DaVita Inc. Announces Management Changes

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate

Chief Legal & Public Affairs Officer recently sold US$1.0m worth of stock

CEO & Executive Director notifies of intention to sell stock

Price target increased by 8.1% to US$96.27

Price target increased by 8.3% to US$94.38

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

What Is DaVita Inc.'s (NYSE:DVA) Share Price Doing?

Price target increased by 8.6% to US$88.80

These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Extensively

Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)

Director recently sold US$108k worth of stock

Are Investors Undervaluing DaVita Inc. (NYSE:DVA) By 40%?

Director exercised options and sold US$106k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 7.0% to US$86.50

DaVita HealthCare Partners Q4 2022 Earnings Preview

Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Is DaVita (NYSE:DVA) A Risky Investment?

DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution